OncLive SOSS

Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma - Episode 17

Future Directions and Unmet Needs in Relapsed/Refractory MCL

February 20, 2024

Grzegorz S. Nowakowski, MD, Jennifer Crombie, MD, Matthew A. Lunning, DO, Peter Martin, MD, Laurie H. Sehn, MD, MPH, Bijal D. Shah, MD

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Current Treatment Options in First-line FL

EP. 2: ASH 2023 Updates on Frontline Therapies in FL

EP. 3: Current Treatment Options in Second-line FL

EP. 4: CAR T-cells as Third-line and Beyond Therapy for FL

EP. 5: Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

EP. 6: Tazemetostat as Third-line and Beyond Therapy for FL

EP. 7: Zanubrutinib as Third-Line and Beyond Therapy for FL

EP. 8: Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL

EP. 9: Choosing CAR T-cells as Third-line and Beyond Therapy for FL

EP. 10: Sequencing Immunotherapy in the Third-line and Beyond Setting for FL

EP. 11: Unmet Needs in Treating Relapsed/Refractory FL

EP. 12: Current Treatment Options in First-Line MCL

EP. 13: ASH 2023 Updates on Frontline Therapies in MCL

EP. 14: Current Treatment Options in Second-line MCL

EP. 15: Current Treatment Options in Third-line MCL

EP. 16: Sequencing Therapies in the Third-Line and Beyond Setting for MCL

EP. 17: Future Directions and Unmet Needs in Relapsed/Refractory MCL

x